Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
NurExone Biologic Logo
NurExone Biologic Growth Score
87
CB Rank
11208
Heat Score
75
NurExone Biologic is developing a biological exosome based technology drug platform to treat damage in the Central Nerve System.
Founded
obfuscation
PublicPost-IPO Equity Haifa, Hefa, Israel11-50 nurexone.com
Biopharma
Biotechnology
Clinical Trials
Overview

NurExone Biologic
Total Funding
obfuscation
Growth Score
87
Heat Score
75

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score87
2 pts
in past quarter
Heat Score 75
0 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
+2 more milestones
See more interactive data and historical milestones on desktop for the best experience

About NurExone Biologic

CB Rank
11208
NurExone Biologic is developing a biological exosome based technology drug platform to treat damage in the Central Nerve System.
Founded
obfuscation
PublicPost-IPO Equity Haifa, Hefa, Israel11-50 nurexone.com
Biopharma
Biotechnology
Clinical Trials

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name NUREXONE BIOLOGIC LTD.
Operating Status Active
Stock Symbol  OTCQB:NRXBF
Company Type For Profit
Founders  Lior Shaltiel
Contact Email info@nurexone.com
Predictions & Insights

Growth Insight

See this Growth Insight
NurExone Biologic is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Biological Exosome-Based Drug Platform
A drug development platform using biological exosomes to treat damage in the central nervous system.

Research & Development

NurExone Biologic is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - NurExone Biologic Logo
Post-IPO Equity - NurExone Biologic
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Israel Innovation Authority Logo
Israel Innovation Authority
Yes
Grant - NurExone Biologic Logo
Grant - NurExone Biologic
—
Israel Innovation Authority Logo
Israel Innovation Authority
Yes
Grant - NurExone Biologic Logo
Grant - NurExone Biologic
—
Israel Innovation Authority Logo
Israel Innovation Authority
Yes
Grant - NurExone Biologic Logo
Grant - NurExone Biologic
—
Israel Innovation Authority Logo
Israel Innovation Authority
Yes
Grant - NurExone Biologic Logo
Grant - NurExone Biologic
—
Israel Innovation Authority Logo
Israel Innovation Authority
Yes
Grant - NurExone Biologic Logo
Grant - NurExone Biologic
—
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 2 Board Members and Advisors 2 Contacts 6

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 14, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 27, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 16, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

508
-13.31%
 in past month

Active Website Tech Count

3NurExone Biologic is actively using 3 technologies for its website, according to BuiltWith. These include Euro and  CommonCrawl Top 5m.

Total IP

3The intellectual property of NurExone Biologic includes 3 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is NurExone Biologic's headquarters? NurExone Biologic is located in Haifa, Hefa, Israel.Who invested in NurExone Biologic? NurExone Biologic is funded by Israel Innovation Authority.When was the last funding round for NurExone Biologic? NurExone Biologic closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are NurExone Biologic's competitors? Alternatives and possible competitors to NurExone Biologic may include Juvena Therapeutics, Strand Therapeutics, and  HAYA Therapeutics.How much funding has NurExone Biologic raised to date? NurExone Biologic has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(ccb7a32 1)
|